Clinical and Experimental Reproductive Medicine

  • 제48권3호
  • /
  • Pages.203-210
  • /
  • 2021
  • /
  • 2233-8233(pISSN)
  • /
  • 2233-8241(eISSN)
대한생식의학회 (The Korean Society for Reproductive Medicine)
권호 표지
DOI QR코드

DOI QR Code

Efficacy of intralipid administration to improve in vitro fertilization outcomes: A systematic review and meta-analysis

  • Han, E Jung (Department of Obstetrics and Gynecology, Fertility Center of CHA Gangnam Medical Center, CHA University School of Medicine) ;
  • Lee, Hye Nam (Department of Obstetrics and Gynecology, Fertility Center of CHA Gangnam Medical Center, CHA University School of Medicine) ;
  • Kim, Min Kyoung (Department of Obstetrics and Gynecology, Fertility Center of CHA Gangnam Medical Center, CHA University School of Medicine) ;
  • Lyu, Sang Woo (Department of Obstetrics and Gynecology, Fertility Center of CHA Gangnam Medical Center, CHA University School of Medicine) ;
  • Lee, Woo Sik (Department of Obstetrics and Gynecology, Fertility Center of CHA Gangnam Medical Center, CHA University School of Medicine)
  • 투고 : 2020.12.01
  • 심사 : 2021.04.06
  • 발행 : 2021.09.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

We performed a systematic review and meta-analysis to evaluate whether intralipid administration improved the outcomes of in vitro fertilization. Online databases (PubMed, Cochrane Library, Medline, and Embase) were searched until March 2020. Only randomized controlled trials (RCTs) that assessed the role of intralipid administration during in vitro fertilization were considered. We analyzed the rates of clinical pregnancy and live birth as primary outcomes. Secondary outcomes included the rates of chemical pregnancy, ongoing pregnancy, and missed abortion. We reviewed and assessed the eligibility of 180 studies. Five RCTs including 840 patients (3 RCTs: women with repeated implantation failure, 1 RCT: women with recurrent spontaneous abortion, 1 RCT: women who had experienced implantation failure more than once) met the selection criteria. When compared with the control group, intralipid administration significantly improved the clinical pregnancy rate (risk ratio [RR], 1.48; 95% confidence interval [CI], 1.23-1.79), ongoing pregnancy rate (RR, 1.82; 95% CI, 1.31-2.53), and live birth rate (RR, 1.85; 95% CI, 1.44-2.38). However, intralipid administration had no beneficial effect on the miscarriage rate (RR, 0.75; 95% CI, 0.48-1.17). A funnel plot analysis revealed no publication bias. Our findings suggest that intralipid administration may benefit women undergoing in vitro fertilization, especially those who have experienced repeated implantation failure or recurrent spontaneous abortion. However, larger, well-designed studies are needed to confirm these findings.

키워드

과제정보

This research was supported by the Technology Innovation Program (or Industrial Strategic Technology Development Program, Grant No. 20003838) funded by the Ministry of Trade, Industry & Energy (MI, Korea).

참고문헌

  1. Zeyneloglu HB, Onalan G. Remedies for recurrent implantation failure. Semin Reprod Med 2014;32:297-305. https://doi.org/10.1055/s-0034-1375182
  2. Kumar P, Mahajan S. Preimplantation and postimplantation therapy for the treatment of reproductive failure. J Hum Reprod Sci 2013;6:88-92. https://doi.org/10.4103/0974-1208.117165
  3. Simon A, Laufer N. Repeated implantation failure: clinical approach. Fertil Steril 2012;97:1039-43. https://doi.org/10.1016/j.fertnstert.2012.03.010
  4. Makrigiannakis A, Petsas G, Toth B, Relakis K, Jeschke U. Recent advances in understanding immunology of reproductive failure. J Reprod Immunol 2011;90:96-104. https://doi.org/10.1016/j.jri.2011.03.006
  5. Kwak-Kim J, Han AR, Gilman-Sachs A, Fishel S, Leong M, Shoham Z. Current trends of reproductive immunology practices in in vitro fertilization (IVF): a first world survey using IVF-Worldwide.com. Am J Reprod Immunol 2013;69:12-20. https://doi.org/10.1111/j.1600-0897.2012.01183.x
  6. Penzias AS. Recurrent IVF failure: other factors. Fertil Steril 2012; 97:1033-8. https://doi.org/10.1016/j.fertnstert.2012.03.017
  7. Beaulieu LM, Vitseva O, Tanriverdi K, Kucukural A, Mick E, Hamburg N, et al. Platelet functional and transcriptional changes induced by intralipid infusion. Thromb Haemost 2016;115:1147-56. https://doi.org/10.1160/th15-09-0739
  8. Granato D, Blum S, Rossle C, Le Boucher J, Malnoe A, Dutot G. Effects of parenteral lipid emulsions with different fatty acid composition on immune cell functions in vitro. JPEN J Parenter Enteral Nutr 2000;24:113-8. https://doi.org/10.1177/0148607100024002113
  9. Mayer K, Meyer S, Reinholz-Muhly M, Maus U, Merfels M, Lohmeyer J, et al. Short-time infusion of fish oil-based lipid emulsions, approved for parenteral nutrition, reduces monocyte proinflammatory cytokine generation and adhesive interaction with endothe lium in humans. J Immunol 2003;171:4837-43. https://doi.org/10.4049/jimmunol.171.9.4837
  10. Meng L, Lin J, Chen L, Wang Z, Liu M, Liu Y, et al. Effectiveness and potential mechanisms of intralipid in treating unexplained recurrent spontaneous abortion. Arch Gynecol Obstet 2016;294:29-39. https://doi.org/10.1007/s00404-015-3922-8
  11. Tang AW, Alfirevic Z, Quenby S. Natural killer cells and pregnancy outcomes in women with recurrent miscarriage and infertility: a systematic review. Hum Reprod 2011;26:1971-80. https://doi.org/10.1093/humrep/der164
  12. Al-Zebeidi J, Agdi M, Lary S, Al-Obaid S, Salim G, Al-Jaroudi D. Effect of empiric intravenous intralipid therapy on pregnancy outcome in women with unexplained recurrent implantation failure undergoing intracytoplasmic sperm injection-embryo transfer cycle: a randomized controlled trial. Gynecol Endocrinol 2020;36:131-4. https://doi.org/10.1080/09513590.2019.1631280
  13. Dakhly DM, Bayoumi YA, Sharkawy M, Gad Allah SH, Hassan MA, Gouda HM, et al. Intralipid supplementation in women with recurrent spontaneous abortion and elevated levels of natural killer cells. Int J Gynaecol Obstet 2016;135:324-7. https://doi.org/10.1016/j.ijgo.2016.06.026
  14. Singh N, Davis AA, Kumar S, Kriplani A. The effect of administration of intravenous intralipid on pregnancy outcomes in women with implantation failure after IVF/ICSI with non-donor oocytes: a randomised controlled trial. Eur J Obstet Gynecol Reprod Biol 2019;240:45-51. https://doi.org/10.1016/j.ejogrb.2019.06.007
  15. Check JH, Check DL. Intravenous intralipid therapy is not beneficial in having a live delivery in women aged 40-42 years with a previous history of miscarriage or failure to conceive despite embryo transfer undergoing in vitro fertilization-embryo transfer. Clin Exp Obstet Gynecol 2016;43:14-5. https://doi.org/10.12891/ceog2166.2016
  16. Martini AE, Jasulaitis S, Fogg LF, Uhler ML, Hirshfeld-Cytron JE. Evaluating the utility of intralipid infusion to improve live birth rates in patients with recurrent pregnancy loss or recurrent implantation failure. J Hum Reprod Sci 2018;11:261-8. https://doi.org/10.4103/jhrs.jhrs_28_18
  17. El-khayat W, El Sadek M. Intralipid for repeated implantation failure (RIF): a randomized controlled trial. Fertil Steril 2015;104:E26. https://doi.org/10.1016/j.fertnstert.2015.07.080
  18. Gamaleldin I, Gomaa MF, Shafik A, Akande V. Intralipid infusion does not improve live birth rates in women with unexplained recurrent implantation failure and may increase the risk of congenital malformations, a double-blinded randomised controlled trial. BJOG 2018;125:31-2.
  19. Asif S, AlAhwany H, Chittawar PB, Nigdelis MP, Toulis KA, Goulis DG, et al. Immune therapies for women with history of unsuccessful implantation undergoing IVF/ICSI treatment: a Cochrane collaboration systematic review. Hum Reprod 2018;33:85.
  20. Tang AW, Alfirevic Z, Turner MA, Drury JA, Small R, Quenby S. A feasibility trial of screening women with idiopathic recurrent miscarriage for high uterine natural killer cell density and randomizing to prednisolone or placebo when pregnant. Hum Reprod 2013;28:1743-52. https://doi.org/10.1093/humrep/det117
  21. Roussev RG, Ng SC, Coulam CB. Natural killer cell functional activity suppression by intravenous immunoglobulin, intralipid and soluble human leukocyte antigen-G. Am J Reprod Immunol 2007; 57:262-9. https://doi.org/10.1111/j.1600-0897.2007.00473.x
  22. Fournier T, Therond P, Handschuh K, Tsatsaris V, Evain-Brion D. PPARgamma and early human placental development. Curr Med Chem 2008;15:3011-24. https://doi.org/10.2174/092986708786848677
  23. Leslie DS, Dascher CC, Cembrola K, Townes MA, Hava DL, Hugendubler LC, et al. Serum lipids regulate dendritic cell CD1 expression and function. Immunology 2008;125:289-301. https://doi.org/10.1111/j.1365-2567.2008.02842.x
  24. Kostenis E. A glance at G-protein-coupled receptors for lipid mediators: a growing receptor family with remarkably diverse ligands. Pharmacol Ther 2004;102:243-57. https://doi.org/10.1016/j.pharmthera.2004.04.005
  25. Desmarais JA, Lopes FL, Zhang H, Das SK, Murphy BD. The peroxisome proliferator-activated receptor gamma regulates trophoblast cell differentiation in mink (Mustela vison). Biol Reprod 2007;77:829-39. https://doi.org/10.1095/biolreprod.107.061929
  26. Clark DA. Intralipid as treatment for recurrent unexplained abortion? Am J Reprod Immunol 1994;32:290-3. https://doi.org/10.1111/j.1600-0897.1994.tb01128.x
  27. Zhang X, Rodriguez-Galan MC, Subleski JJ, Ortaldo JR, Hodge DL, Wang JM, et al. Peroxisome proliferator-activated receptor-gamma and its ligands attenuate biologic functions of human natural killer cells. Blood 2004;104:3276-84.
  28. Delerive P, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 2001;169:453-9. https://doi.org/10.1677/joe.0.1690453
  29. Roussev RG, Acacio B, Ng SC, Coulam CB. Duration of intralipid's suppressive effect on NK cell's functional activity. Am J Reprod Immunol 2008;60:258-63. https://doi.org/10.1111/j.1600-0897.2008.00621.x
  30. Kowalewski MP, Meyer A, Hoffmann B, Aslan S, Boos A. Expression and functional implications of peroxisome proliferator-activated receptor gamma (PPARγ) in canine reproductive tissues during normal pregnancy and parturition and at antiprogestin induced abortion. Theriogenology 2011;75:877-86. https://doi.org/10.1016/j.theriogenology.2010.10.030
  31. Kwak JY, Kwak FM, Ainbinder SW, Ruiz AM, Beer AE. Elevated peripheral blood natural killer cells are effectively downregulated by immunoglobulin G infusion in women with recurrent spontaneous abortions. Am J Reprod Immunol 1996;35:363-9. https://doi.org/10.1111/j.1600-0897.1996.tb00495.x
  32. Coulam CB, Acacio B. Does immunotherapy for treatment of reproductive failure enhance live births? Am J Reprod Immunol 2012;67:296-304. https://doi.org/10.1111/j.1600-0897.2012.01111.x